Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating expenses:
Research and development	$ 6,811,609	$ 6,654,257	$ 10,901,186	$ 13,418,105
General and administrative	15,633,738	3,343,325	19,619,036	6,769,158
Acquired in-process research and development	76,020,184		76,020,184
Total operating expenses	98,465,531	9,997,582	106,540,406	20,187,263
Other income (expense):
Interest income (expense), net	52,491	(588)	54,462	(1,645)
Foreign currency gain (loss)	154,566	(252,843)	290,777	269,140
Total other income (loss)	207,057	(253,431)	345,239	267,495
Net loss	(98,258,474)	(10,251,013)	(106,195,167)	(19,919,768)
Other comprehensive loss:
Foreign currency translation	157,655	193,020	92,150	(209,830)
Total comprehensive loss	$ (98,100,819)	$ (10,057,993)	$ (106,103,017)	$ (20,129,598)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (4.34)	$ (0.48)	$ (4.77)	$ (0.94)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (4.34)	$ (0.48)	$ (4.77)	$ (0.94)
Weighted-average common shares outstanding, basic (in shares)	22,661,835	21,186,827	22,283,783	21,186,827
Weighted-average common shares outstanding, diluted (in shares)	22,661,835	21,186,827	22,283,783	21,186,827